VOR
Vor Biopharma Inc (VOR)
Healthcare • NASDAQ • $16.94+5.35%
- Symbol
- VOR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $16.94
- Daily Change
- +5.35%
- Market Cap
- $917.91M
- Trailing P/E
- N/A
- Forward P/E
- -4.54
- 52W High
- $65.80
- 52W Low
- $3.06
- Analyst Target
- $37.50
- Dividend Yield
- N/A
- Beta
- 1.75
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Company websiteResearch VOR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.